enGene Therapeutics Inc Financials
This page shows enGene Therapeutics Inc (ENGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The visible mechanic is research-led cash consumption: R&D acceleration drives losses while financing, not operations, supplies funding.
R&D escalation more than doubled from FY2024 to FY2025 while the operating loss nearly doubled, making expense growth—not depreciation—the dominant visible driver. Because FY2025 operating cash flow of-$99.2M closely tracked the-$123.2M operating loss, the reported deficit is predominantly cash-consuming research activity rather than an accounting-only charge.
Financing inflow fell sharply from
The reported liquidity comparison equals 24.5 months of the latest annual operating outflow, a balance-sheet measure rather than a forecast. Debt-to-equity rose from 0.1x in FY2024 to 0.3x in FY2025, while equity remained positive, indicating leverage is increasing from a low base.
Financial Health Signals
enGene Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
enGene Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
enGene Therapeutics Inc reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
enGene Therapeutics Inc reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
enGene Therapeutics Inc's EBITDA was -$122.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 97.9% from the prior year.
enGene Therapeutics Inc reported -$117.3M in net income in fiscal year 2025. This represents a decrease of 112.7% from the prior year.
enGene Therapeutics Inc earned $2.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 56.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
enGene Therapeutics Inc recorded an outflow of $100.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 104.7% from the prior year.
enGene Therapeutics Inc held $50.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
enGene Therapeutics Inc paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
enGene Therapeutics Inc's ROE was -69.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 49.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
enGene Therapeutics Inc invested $94.5M in research and development in fiscal year 2025. This represents an increase of 146.6% from the prior year.
enGene Therapeutics Inc invested $1.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 60.5% from the prior year.
Not reported for fiscal year 2025.
ENGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $22.2M-0.3% | $22.3M | N/A | $22.6M+11.7% | $20.2M+1.2% | $20.0M | N/A | $11.5M |
| SG&A Expenses | $9.8M+9.4% | $8.9M | N/A | $7.4M+6.6% | $6.9M+4.2% | $6.6M | N/A | $5.2M |
| Operating Income | -$32.0M-2.5% | -$31.2M | N/A | -$29.9M-10.4% | -$27.1M-1.9% | -$26.6M | N/A | -$16.8M |
| Interest Expense | $745K+1.8% | $732K | N/A | $758K+3.3% | $734K-2.4% | $752K | N/A | $751K |
| Income Tax | $0 | $0 | N/A | $239K-0.4% | $240K+1233.3% | $18K | N/A | -$29K |
| Net Income | -$30.2M-1.6% | -$29.8M | N/A | -$29.0M-12.3% | -$25.8M-4.9% | -$24.6M | N/A | -$14.1M |
| EPS (Diluted) | -$0.43-197.7% | $0.44-39.7% | $0.73+28.1% | $0.57+211.8% | -$0.51-206.3% | $0.48+41.2% | $0.34+6.3% | $0.32 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
ENGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $307.5M-8.8% | $337.1M+52.2% | $221.5M-9.8% | $245.6M-7.9% | $266.7M-6.7% | $285.9M-8.1% | $311.2M+16.6% | $266.9M |
| Current Assets | $270.0M-6.6% | $289.2M+43.6% | $201.4M-4.7% | $211.3M-7.3% | $228.0M+2.5% | $222.3M-10.1% | $247.4M-5.8% | $262.7M |
| Cash & Equivalents | $29.8M-18.5% | $36.6M-27.0% | $50.2M+53.7% | $32.6M-43.3% | $57.5M-7.7% | $62.3M-64.0% | $173.0M-32.9% | $257.7M |
| Total Liabilities | $52.4M-5.8% | $55.6M+3.4% | $53.8M+19.8% | $44.9M+14.0% | $39.4M+9.4% | $36.0M-6.7% | $38.6M+5.5% | $36.5M |
| Current Liabilities | $21.5M-12.7% | $24.6M-23.0% | $32.0M+56.5% | $20.4M+13.5% | $18.0M+39.0% | $13.0M-11.6% | $14.7M+8.9% | $13.5M |
| Total Equity | $255.2M-9.4% | $281.5M+67.9% | $167.7M-16.4% | $200.7M-11.7% | $227.3M-9.1% | $249.9M-8.3% | $272.6M+18.4% | $230.3M |
| Retained Earnings | -$432.0M-7.5% | -$401.8M-8.0% | -$372.0M-11.3% | -$334.2M-9.5% | -$305.2M-9.2% | -$279.3M-9.7% | -$254.7M-6.4% | -$239.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ENGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$30.5M-5.5% | -$28.9M-15.8% | -$25.0M+2.6% | -$25.6M-11.7% | -$22.9M+10.7% | -$25.7M-31.3% | -$19.6M-172.5% | -$7.2M |
| Capital Expenditures | $98K-35.9% | $153K-65.0% | $437K-37.9% | $704K+1464.4% | $45K-84.9% | $299K+25.6% | $238K+11800.0% | $2K |
| Free Cash Flow | -$30.6M-5.3% | -$29.1M-14.4% | -$25.4M+3.6% | -$26.3M-14.6% | -$23.0M+11.6% | -$26.0M-31.2% | -$19.8M-175.7% | -$7.2M |
| Investing Cash Flow | $23.6M+118.7% | -$126.3M-411.8% | $40.5M+2836.9% | $1.4M-92.3% | $17.9M+121.1% | -$85.0M+32.2% | -$125.3M-6263200.0% | -$2K |
| Financing Cash Flow | $74K-99.9% | $141.7M+7015.0% | $2.0M+398.5% | -$667K-435.2% | $199K+19800.0% | $1K-100.0% | $60.2M+117860.8% | $51K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ENGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -11.8%-1.3pp | -10.6% | N/A | -14.4%-3.1pp | -11.4%-1.5pp | -9.8% | N/A | -6.1% |
| Return on Assets | -9.8%-1.0pp | -8.8% | N/A | -11.8%-2.1pp | -9.7%-1.1pp | -8.6% | N/A | -5.3% |
| Current Ratio | 12.57+0.8x | 11.75+5.5x | 6.30-4.0x | 10.34-2.3x | 12.66-4.5x | 17.16+0.3x | 16.87-2.6x | 19.52 |
| Debt-to-Equity | 0.210.0x | 0.20-0.1x | 0.32+0.1x | 0.22+0.1x | 0.170.0x | 0.140.0x | 0.140.0x | 0.16 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where enGene Therapeutics Inc Ranks
Frequently Asked Questions
Is enGene Therapeutics Inc profitable?
No, enGene Therapeutics Inc (ENGN) reported a net income of -$117.3M in fiscal year 2025.
What is enGene Therapeutics Inc's EBITDA?
enGene Therapeutics Inc (ENGN) had EBITDA of -$122.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is enGene Therapeutics Inc's return on equity (ROE)?
enGene Therapeutics Inc (ENGN) has a return on equity of -69.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is enGene Therapeutics Inc's free cash flow?
enGene Therapeutics Inc (ENGN) recorded an outflow of $100.7M in free cash flow during fiscal year 2025. This represents a -104.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is enGene Therapeutics Inc's operating cash flow?
enGene Therapeutics Inc (ENGN) recorded an outflow of $99.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are enGene Therapeutics Inc's total assets?
enGene Therapeutics Inc (ENGN) had $221.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are enGene Therapeutics Inc's capital expenditures?
enGene Therapeutics Inc (ENGN) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does enGene Therapeutics Inc spend on research and development?
enGene Therapeutics Inc (ENGN) invested $94.5M in research and development during fiscal year 2025.
What is enGene Therapeutics Inc's current ratio?
enGene Therapeutics Inc (ENGN) had a current ratio of 6.30 as of fiscal year 2025, which is generally considered healthy.
What is enGene Therapeutics Inc's debt-to-equity ratio?
enGene Therapeutics Inc (ENGN) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is enGene Therapeutics Inc's return on assets (ROA)?
enGene Therapeutics Inc (ENGN) had a return on assets of -53.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does enGene Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, enGene Therapeutics Inc (ENGN) held $202.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $99.2M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is enGene Therapeutics Inc's Piotroski F-Score?
enGene Therapeutics Inc (ENGN) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are enGene Therapeutics Inc's earnings high quality?
enGene Therapeutics Inc (ENGN) reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can enGene Therapeutics Inc cover its interest payments?
enGene Therapeutics Inc (ENGN) reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.